NGS Reagents Market to Quadruple, Surging to USD 3.95 Billion by 2031 on Precision Medicine Wave
Boston, 04th June 2025 – The global market for Next-Generation Sequencing reagents is projected to leap from USD 1.85 billion in 2024 to USD 3.95 billion by 2031, registering a robust CAGR of 11.2%, according to a new report by Clearview Market Insights (CVMI).
“As sequencing becomes a frontline diagnostic
tool, laboratories are demanding reagents that are faster, more robust, and
automation-ready,” said Dr. Aisha Rahman, Principal Analyst at CVMI. “This
double-digit growth trajectory underscores how integral consumables are to the
precision-medicine ecosystem.”
Request Sample
@ https://clearviewmarketinsights.com/report-details/global-next-generation-sequencing-ngs-reagents-market/
Market Catalysts
Oncology Domination – Comprehensive genomic profiling volumes are
expanding by 18% per year, with each tumor type panel consuming up to four
reagent kits per sample.
Automation Imperative – Labs deploying cartridge-based robots reduced
hands-on prep time from 90 to 25 minutes, promoting the adoption of
compatible chemistries.
Lyophilised Leap – CVMI projects that ambient stable mixes will command
a 28% revenue share by 2027, unlocking markets in Africa, Southeast Asia, and
remote U.S. testing sites.
Public‑Health Permanence – WHO’s Genomic Surveillance Strategy 2025–2035
allocates USD 1.8 billion for sequencing capacity building, ensuring a baseline
reagent demand for pathogen monitoring.
Agri‑genomics Upswing – Climate-resilient crop breeding programs
contribute a reliable 13% CAGR niche to total reagent sales.
Competitive Highlights
Illumina remains the market
leader with a 20% share, propelled by its SBS chemistry and Prep-X Rapid kits.
Thermo Fisher follows with an 18% share, while Genexus-linked instrument
cartridges are cutting TAT for local path labs. QIAGEN (14%) is leveraging
bead-based purification to outperform in low-input RNA preps, while Roche (10%)
advances ctDNA-specific enzymes. Agilent’s 8% share is rising due to the
strength of AI-designed SureSelect probes that reduce off-target reads by 50%.
Regional Momentum
North America – New FDA LDT rule accelerates the shift to
IVDR-aligned, fully validated reagent lots; NIH’s All of Us program boosts
sample volumes.
Europe – IVDR enforcement in May 2026 will trigger widespread kit
revalidation, benefiting vendors with CE-ready pipelines.
Asia‑Pacific: China’s volume–based procurement added 500 sequencers
in 2024, and India’s GenomeIndia ramps to 10,000 exomes annually.
Latin America & MEA – Pan-American Health Organization pathogen
grants and Africa CDC network promote sustainable reagent orders.
Key Milestones 2024‑2025
|
Quarter |
Event |
Impact |
|
Q4 2023 |
Illumina launches 2‑hour Prep‑X kit |
Cuts library TAT by 40 % |
|
Q1 2024 |
QIAGEN‑Stanford
debut cfRNA ultra‑low kit |
Opens 10‑ng
input oncology liquid biopsy market |
|
Q2 2024 |
Thermo Fisher ships refillable Genexus
cartridges |
Reduces plastic waste 60 % and ASP 12 % |
|
Q4 2024 |
Roche
wins CE‑IVD for AVENIO Tumour Tissue kit |
Unlocks
EU reimbursements for ctDNA workflows |
|
Q1 2025 |
Agilent acquires Velion microfluidics |
Integrates prep‑on‑cartridge for SureSelect
XT HS4 |
Technology Trends
Microfluidic Prep‑Cartridges – On‑chip
fragmentation & cleanup cut reagent usage by 65 %.
AI‑Optimised Polymerases – Deep‑learning‑guided mutations extend
processivity, reducing error rates 70 %.
Green Packaging – Bio‑PET reagent vials slash CO₂ footprint by 45 %.
Encrypted Molecular Tags – Enable anti‑counterfeiting traceability
through supply chain.
Looking Ahead to 2031
2026 – Ambient‑stable reagent mixes hit 25 %
market share.
2027 – Fully automated “sample‑in → report‑out” NGS benches become
mainstream in Tier‑2 hospitals.
2028 – Public‑health labs sequence 1.2 million pathogen genomes
annually, ensuring baseline reagent demand.
2029 – Pay‑per‑sample reagent leasing models emerge, mirroring printer
ink subscriptions.
2030 – AI‑guided chemistries halve reaction times, pushing daily library
capacity beyond 1,000 samples per robot.
2031 – Over 70 % of global NGS libraries are prepared on walk‑away
microfluidic cartridges.
For more
insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and
consulting firm providing in-depth industry analysis and strategic
recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment